Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 5, 2012, Pages 1043-1047

  Hesketh, Paul J ^a   Sanz Altamira, Pedro ^b   Bushey, Julie ^c   Hesketh, Ann M ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Commonwealth Hematology Oncology ^*  (United States)

^c Holy Family Hospital   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Nausea; Oxaliplatin; Vomiting

Indexed keywords

DEXAMETHASONE; DOLASETRON MESILATE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; ONDANSETRON; OXALIPLATIN; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MORBIDITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; REVIEW; SEX RATIO;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLORECTAL NEOPLASMS; DEXAMETHASONE; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 84863446959     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1180-2     Document Type: Review

References (26)

1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482-2494
2. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932-2947
3. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
4. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117-1122
5. du Bois A, Meerpohl HG, Vach W et al (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatinpretreated patients: a study with ondansetron. Eur J Cancer 28:450-457
6. Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14:2242-2249
7. Osoba D, Zee B, Peter J et al (1997) Determinants of post chemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-123
8. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
9. Capdevilla J, Elez E, Peralta S et al (2008) Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 8:1223-1236
10. Mathe G, Kidani Y, Triana K et al (1986) A phase I trial of trans-1-diaminocyclohexane oxalatoplatinum (1-OHP). Biomed Pharmacother 40:372-376
11. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303
12. Becouarn Y, Ychou M, Ducreux M et al (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16(8):2739-2744
13. Diaz-Rubio E, Sastre J, Zaniboni A et al (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105-108
14. Kris MG, Gralla RJ, Clark RA et al (1985) Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384
15. Martin M, Diaz-Rubio E, Sanchez A et al (1990) The natural course of emesis after carboplatin treatment. Acta Oncol 29:593-595
16. du Bois A, Vach W, Cramer-Giraud U et al (1995) Pattern of carboplatin-induced emesis. Anticancer Drugs 6:645-651
17. Tavorath R, Hesketh PJ (1996) Drug treatment of chemotherapyinduced delayed emesis. Drugs 52(5):639-648
18. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090-3098
19. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebocontrolled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21 (22):4112-4119
20. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830.
21. [Erratum, J Clin Oncol 2005; 23:5851.]
22. De Wit R, Herrstedt J, Rapoport B et al (2004) The oral NK (1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 40:403-410
23. Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555
24. Gralla RJ, Rapoport B, Brown C et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy in breast and non-breast cancers. MASCC/ISOO, International Symposium, Vancouver, Canada
25. Kris MG, Gralla RJ, Tyson LB et al (1989) Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114
26. Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559